Capstone Investment Advisors
NBIX icon

Capstone Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Capstone Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,040
Closed -$427K – 1905
2025
Q3 		$427K Sell
3,040
-1,562
-34% -$212K ﹤0.01% 1484
2025
Q2 		$578K Buy
4,602
+1,451
+46% +$166K ﹤0.01% 1073
2025
Q1 		$349K Buy
+3,151
New +$399K ﹤0.01% 1155
2024
Q2 		– Sell
-5,652
Closed -$780K – 2326
2024
Q1 		$780K Buy
5,652
+3,258
+136% +$445K ﹤0.01% 1294
2023
Q4 		$315K Sell
2,394
-954
-28% -$110K ﹤0.01% 1570
2023
Q3 		$377K Buy
+3,348
New +$353K ﹤0.01% 1473
2018
Q1 		– Sell
-6,469
Closed -$501K – 484
2017
Q4 		$501K Buy
+6,469
New +$441K 0.01% 269
2017
Q3 		– Sell
-6,800
Closed -$312K – 674
2017
Q2 		$312K Sell
6,800
-8,507
-56% -$413K 0.01% 481
2017
Q1 		$662K Buy
+15,307
New +$656K 0.02% 523

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capstone Investment Advisors's NBIX Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 3,040 shares — an estimated $427K sold.

Capstone Investment Advisors first reported a position in NBIX in Q1 2017 and held it in 9 quarters. The position peaked at $780K in Q1 2024. 733 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 3,040 Neurocrine Biosciences shares in Q4 2025, an estimated $427K.
  • Capstone Investment Advisors first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 9 quarters.
  • Capstone Investment Advisors's Neurocrine Biosciences position peaked at $780K in Q1 2024.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.